Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

Laura N. Eadie, Elias Lagonik, Elyse C. Page, Caitlin E. Schutz, Susan L. Heatley, Barbara J. McClure, Michelle O. Forgione, David T. Yeung, Timothy P. Hughes, Deborah L. White

Blood (2024) 144 (9): 1022–1026.

https://doi.org/10.1182/blood.2024024776

Published: 2024

Includes: Supplemental data

Journal Articles

Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present

Laura N Eadie, Caitlin E Schutz, Elyse C Page, Tace S Conlin, Susan L Heatley, Elias Lagonik, Jacqueline A Rehn, David T Yeung, Timothy P Hughes, Deborah L White

Blood (2023) 142 (Supplement 1): 1602.

https://doi.org/10.1182/blood-2023-184647

Published: 2023

Journal Articles

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Blood (2023) 142 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2023-178473

Published: 2023

Journal Articles

Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis

Susan L Heatley, Elyse C Page, Laura N Eadie, Barbara J McClure, Jacqueline Rehn, David T Yeung, Michael Philip Osborn, Tamas Revesz, Maria Kirby, Deborah L White

Blood (2021) 138 (Supplement 1): 1317.

https://doi.org/10.1182/blood-2021-150086

Published: 2021

Journal Articles

HMGN1 expression Predisposes Down Syndrome Patients to Develop P2RY8-CRLF2 acute Lymphoblastic Leukemia

Elyse C Page, Susan L Heatley, Jacqueline Rehn, David T Yeung, Paul Q Thomas, Deborah L White

Blood (2021) 138 (Supplement 1): 4332.

https://doi.org/10.1182/blood-2021-151848

Published: 2021

Journal Articles

Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities

Laura N Eadie, BSc, PhD, Jacqueline Rehn, MSc(BioTech), Susan L Heatley, PhD MD, Barbara J McClure, BSc,PhD, Caitlin Schutz Schutz, BSc (Hons), James Breen, BSc,PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Rosemary Sutton, BSc MSc PhD, Deborah L White, PhDFFSc(RCPA)

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-138995

Published: 2020

Journal Articles

Inducible Knockout of HMGN1 in an In Vivo xenograft Model Reduces Down Syndrome Leukemic Burden and Increases Survival Outcomes

Elyse C Page, BSc, Susan L Heatley, PhD MD, Paul Q Thomas, PhD, Deborah L White, PhDFFSc(RCPA)

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-138620

Published: 2020

Journal Articles

Persistent Activation of JAK/STAT Signaling Plays an Important Role in in Vitro Jaki Resistance in TYK2- rearranged B-Cell Acute Lymphoblastic Leukaemia

Paniz Tavakoli, Laura N Eadie, BSc, PhD, Susan L Heatley, PhD MD, John B Bruning, BSc,PhD, Deborah L White, PhDFFSc(RCPA)

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-139048

Published: 2020

Journal Articles

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Jacqueline Rhen, BSc MSc MD, Susan L Heatley, PhD MD, Barbara McClure, BSc (Hons) PhD, Laura N Eadie, BSc (Hons) PhD, Jimmy Breen, BSc (Hons) PhD, Caitlin Schutz Schutz, BSc (Hons), Toby N Trahair, MBBS FRACP PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Luciano Dalla-Pozza, MBBS FRACP, Rosemary Sutton, BSc MSc PhD, Kenneth F Bradstock, BSc(MD, MBBS, PhD FRACP, FRCPA, Michael Philip Osborn, MB, BS, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3949.

https://doi.org/10.1182/blood-2019-127788

Published: 2019

Journal Articles

A Novel Role for HMGN1 in Down Syndrome Acute Lymphoblastic Leukemia

Elyse C Page, BSc, Susan L Heatley, PhD MD, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Paul Q Thomas, PhD, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 1462.

https://doi.org/10.1182/blood-2019-126244

Published: 2019

Journal Articles

In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy

Kartini Asari, Susan L Heatley, PhD MD, Teresa Sadras, PhD, Tamara M Leclercq, PhD, Stephen Fitter, PhD, Chung Hoow Kok, PhD, Andrew C W Zannettino, PhD, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, Deborah L White, PhD FFSc (RCPA)

Blood (2016) 128 (22): 3957.

https://doi.org/10.1182/blood.V128.22.3957.3957

Published: 2016

Journal Articles

High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment

Blood (2015) 126 (23): 1419.

https://doi.org/10.1182/blood.V126.23.1419.1419

Published: 2015

Journal Articles

Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project

Jinghui Zhang, PhD, Li Ding, PhD, Linda Holmfeldt, PhD, Gang Wu, PhD, Susan L. Heatley, Ph.D., Debbie Payne-Turner, John Easton, PhD, Xiang Chen, PhD, Jianmin Wang, PhD, Michael Rusch, BA, Charles Lu, PhD, Shann-Ching Chen, PhD, Racquel Collins-Underwood, PhD, Jing Ma, PhD, Kathryn G. Roberts, PhD, Stanley Pounds, PhD, Lei Wei, PhD, Anatoly Ulyanov, PhD, Jared Becksfort, Pankaj Gupta, Robert Huether, PhD, Richard Kriwacki, PhD, Daniel McGoldrick, David Zhao, Daniel Alford, Stephen Espy, Kiran Chand Bobba, Guangchun Song, Deqing Pei, MS, Cheng Cheng, PhD, Stefan Roberts, Michael Barbato, Dario Campana, MD, PhD, Elaine Coustan-Smith, MS, William E. Evans, PharmD, Sheila A Shurtleff, PhD, Maria Kleppe, Jan Cools, PhD, Kristin Shimano, Michelle L. Hermiston, MD, PhD, Sergei Doulatov, PhD, Kolja Eppert, PhD, Elisa Laurenti, PhD, Faiyaz Notta, PhD, John E Dick, PhD, Giuseppe Basso, MD PhD, Stephen P. Hunger, MD, Mignon L Loh, MD, Meenakshi Devidas, PhD, Brent L. Wood, MD, PhD, Stuart S. Winter, MD, Kimberly Dunsmore, MD, Robert S. Fulton, MS, Lucinda A. Fulton, MS, Xin Hong, PhD, Christopher C. Harris, BS, David J. Dooling, PhD, Kerri Ochoa, Kimberly J Johnson, John C Obenauer, Ching-Hon Pui, MD, Susana C. Raimondi, PhD, Clayton W Naeve, PhD, Timothy J Ley, MD, Elaine R Mardis, PhD, Richard K Wilson, PhD, James R Downing, MD, Charles G Mullighan, MBBS, MD, FRACP, FRCPA, MSc

Blood (2011) 118 (21): 68.

https://doi.org/10.1182/blood.V118.21.68.68

Published: 2011

Journal Articles

CREBBP Mutations In Relapsed Acute Lymphoblastic Leukemia

Charles Mullighan, MBBS, MD, FRACP, FRCPA, MSc, Jinghui Zhang, Ph.D., Lawryn H. Kasper, Ph.D., Stephanie Lerach, Ph.D., Debbie Payne-Turner, Letha A Phillips, J. Racquel Collins-Underwood, Ph.D., Susan L. Heatley, Ph.D., Jing Ma, Ph.D., Kenneth Buetow, Ph.D., Ching-Hon Pui, MD, Paul K. Brindle, Ph.D., James R. Downing, MD

Blood (2010) 116 (21): 413.

https://doi.org/10.1182/blood.V116.21.413.413

Published: 2010

Journal Articles

Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation

Charles G. Mullighan, Susan L. Heatley, Silke Danner, Melinda M. Dean, Kathleen Doherty, Uwe Hahn, Kenneth F. Bradstock, Robyn Minchinton, Anthony P. Schwarer, Jeff Szer, Peter G. Bardy

Blood (2008) 112 (5): 2120–2128.

https://doi.org/10.1182/blood-2007-07-100222

Published: 2008

Includes: Supplemental data

NARROW

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis

HMGN1 expression Predisposes Down Syndrome Patients to Develop P2RY8-CRLF2 acute Lymphoblastic Leukemia

Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities

Inducible Knockout of HMGN1 in an In Vivo xenograft Model Reduces Down Syndrome Leukemic Burden and Increases Survival Outcomes

Persistent Activation of JAK/STAT Signaling Plays an Important Role in in Vitro Jaki Resistance in TYK2- rearranged B-Cell Acute Lymphoblastic Leukaemia

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

A Novel Role for HMGN1 in Down Syndrome Acute Lymphoblastic Leukemia

In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy

High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment

Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project

CREBBP Mutations In Relapsed Acute Lymphoblastic Leukemia

Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only